General Biologicals Corporation (TPEX:4117)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
12.70
-0.90 (-6.62%)
Jun 18, 2026, 2:59 PM CST
Market Cap772.48M -35.4%
Revenue (ttm)215.74M -14.4%
Net Income465.84M
EPS7.44
Shares Out 60.83M
PE Ratio1.71
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume609,004
Open13.50
Previous Close13.60
Day's Range12.35 - 14.05
52-Week Range3.50 - 19.10
Beta0.85
AnalystsBuy
Price Target38.00 (+199.21%)
Earnings DateAug 12, 2026

About General Biologicals

General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening services for hepatitis and HIV; and biomaterial, such as antibody biomaterials and human plasma. Additionally, it offers a range of oral care products... [Read more]

Sector Healthcare
Founded 1984
Employees 81
Stock Exchange Taipei Exchange
Ticker Symbol 4117
Full Company Profile

Financial Performance

Financial Statements